perimenopause and glp 1 GLP-1 Agonists in Perimenopause: Unique Risks Potential Opportunities 7 Insights on Alcohol and

All studies seem to have reported all data which gives a low risk of incomplete outcome data as "attrition bias"

Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T: Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

For behavioral studies, data were analyzed by ANCOVA, or repeated-measures one-way or two-way ANOVA followed by Tukeys or Bonferronis post hoc test as appropriate

There is no routine clinical test to directly measure GLP-1 function in standard NHS practice

The first of these drugs, exenatide, was approved by the FDA in 2005